Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2018 · 10-Q
Revenue—
Net Income-$7.80M-$7.80MN/M vs Q2 2017 EPS Diluted-$0.45-$0.45N/M vs Q2 2017 Operating Income-$7,594,000N/M Operating Cash Flowderived-$5,538,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,675,000N/M ended Jun 30, 2018 · filed Aug 7, 2018 · 38 d after period end